Showing 85 to 96 of 152 results
EU Pharmaceutical Stocks Plummet on US Tariff Threat
The threat of new US tariffs on pharmaceutical imports caused a significant drop in European and Indian pharmaceutical stocks, prompting warnings of a 'flight risk' to the US and leading EU pharmaceutical companies to request immediate policy changes from the EU President to prevent billions of euro...
EU Pharmaceutical Stocks Plummet on US Tariff Threat
The threat of new US tariffs on pharmaceutical imports caused a significant drop in European and Indian pharmaceutical stocks, prompting warnings of a 'flight risk' to the US and leading EU pharmaceutical companies to request immediate policy changes from the EU President to prevent billions of euro...
Progress
40% Bias Score
Starmer Unveils Economic Plan to Counter US Tariffs
Keir Starmer announced measures to support the UK car and pharmaceutical industries following US tariffs, including relaxing electric car targets and streamlining clinical trials, in response to market downturns and warnings of an "age of insecurity".
Starmer Unveils Economic Plan to Counter US Tariffs
Keir Starmer announced measures to support the UK car and pharmaceutical industries following US tariffs, including relaxing electric car targets and streamlining clinical trials, in response to market downturns and warnings of an "age of insecurity".
Progress
40% Bias Score
US Pharmaceutical Tariffs: Relief, But EU Remains Wary
While President Trump's threatened 25% tariffs on pharmaceuticals haven't materialized yet, the EU remains wary of future US tariffs, given the US's significant reliance on \$127 billion worth of pharmaceutical imports from the EU in 2024, impacting economies like Ireland and Belgium.
US Pharmaceutical Tariffs: Relief, But EU Remains Wary
While President Trump's threatened 25% tariffs on pharmaceuticals haven't materialized yet, the EU remains wary of future US tariffs, given the US's significant reliance on \$127 billion worth of pharmaceutical imports from the EU in 2024, impacting economies like Ireland and Belgium.
Progress
36% Bias Score
Trump's Tariffs Threaten €85 Billion in EU Exports
The Trump administration's "Liberation Day" on April 2nd imposed potentially 20% tariffs on EU imports to the US, threatening €85 billion in EU exports and significantly impacting the automotive and pharmaceutical sectors, with Germany, Slovakia, and Denmark particularly vulnerable.
Trump's Tariffs Threaten €85 Billion in EU Exports
The Trump administration's "Liberation Day" on April 2nd imposed potentially 20% tariffs on EU imports to the US, threatening €85 billion in EU exports and significantly impacting the automotive and pharmaceutical sectors, with Germany, Slovakia, and Denmark particularly vulnerable.
Progress
40% Bias Score
US and EU Avert Pharmaceutical Tariff Clash, But Concerns Remain
The US and EU avoided imposing tariffs on pharmaceutical products, averting a potential crisis in a sector where the US imported \$127 billion worth of goods from the EU in 2024, although concerns remain about future trade disputes.
US and EU Avert Pharmaceutical Tariff Clash, But Concerns Remain
The US and EU avoided imposing tariffs on pharmaceutical products, averting a potential crisis in a sector where the US imported \$127 billion worth of goods from the EU in 2024, although concerns remain about future trade disputes.
Progress
40% Bias Score
EU's Slow Drug Approvals Delay Patient Access to Life-Saving Medicines
By 2050, one-third of the EU population will be over 65, underscoring the urgent need for health system modernization. Slower drug approvals (120 days behind the US and Japan) cause a 20-month delay in patient access to new medicines compared to the US, impacting those with cancer, cardiovascular di...
EU's Slow Drug Approvals Delay Patient Access to Life-Saving Medicines
By 2050, one-third of the EU population will be over 65, underscoring the urgent need for health system modernization. Slower drug approvals (120 days behind the US and Japan) cause a 20-month delay in patient access to new medicines compared to the US, impacting those with cancer, cardiovascular di...
Progress
52% Bias Score
Healthcare Sector Volatility: Trump's Policies and Market Uncertainties
Recent market volatility, driven by Trump's trade policies and US market uncertainties, has negatively impacted the healthcare sector, particularly pharmaceutical companies, despite its generally defensive nature and strong long-term growth prospects due to an aging population and technological adva...
Healthcare Sector Volatility: Trump's Policies and Market Uncertainties
Recent market volatility, driven by Trump's trade policies and US market uncertainties, has negatively impacted the healthcare sector, particularly pharmaceutical companies, despite its generally defensive nature and strong long-term growth prospects due to an aging population and technological adva...
Progress
36% Bias Score
Senate Advances Six Bills to Reform Drug Patent System
The Senate Judiciary Committee advanced six bipartisan bills to reform the drug patent system, aiming to curb anti-competitive practices like "patent thickets" and "product hopping" that inflate drug prices; the legislation's success remains uncertain due to past failures.
Senate Advances Six Bills to Reform Drug Patent System
The Senate Judiciary Committee advanced six bipartisan bills to reform the drug patent system, aiming to curb anti-competitive practices like "patent thickets" and "product hopping" that inflate drug prices; the legislation's success remains uncertain due to past failures.
Progress
48% Bias Score
Trump Tariffs: Pharmaceutical CEO Warns of Economic Consequences
Eli Lilly CEO David Ricks states that President Trump's tariffs are a watershed moment in US economic history, impacting pharmaceutical investment and potentially reducing research and development; the UK's life sciences sector is also in decline due to slow regulation and poor uptake of new medicin...
Trump Tariffs: Pharmaceutical CEO Warns of Economic Consequences
Eli Lilly CEO David Ricks states that President Trump's tariffs are a watershed moment in US economic history, impacting pharmaceutical investment and potentially reducing research and development; the UK's life sciences sector is also in decline due to slow regulation and poor uptake of new medicin...
Progress
44% Bias Score
US Exempts Pharmaceuticals from Tariffs, but Future Risks Remain
The White House exempted pharmaceuticals from reciprocal tariffs, averting a potential 25% tax on \$127 billion in 2024 EU-US trade; however, future tariffs remain a significant concern for the EU, prompting a meeting between the European Commission and the pharmaceutical industry.
US Exempts Pharmaceuticals from Tariffs, but Future Risks Remain
The White House exempted pharmaceuticals from reciprocal tariffs, averting a potential 25% tax on \$127 billion in 2024 EU-US trade; however, future tariffs remain a significant concern for the EU, prompting a meeting between the European Commission and the pharmaceutical industry.
Progress
40% Bias Score
US-EU Pharmaceutical Tariff Dispute: Temporary Reprieve, Long-Term Concerns
The pharmaceutical sector escaped US tariffs for now, but the EU remains wary due to US policies encouraging relocation of manufacturing to the EU, primarily in Ireland, creating significant economic dependence and potentially long-term consequences.
US-EU Pharmaceutical Tariff Dispute: Temporary Reprieve, Long-Term Concerns
The pharmaceutical sector escaped US tariffs for now, but the EU remains wary due to US policies encouraging relocation of manufacturing to the EU, primarily in Ireland, creating significant economic dependence and potentially long-term consequences.
Progress
36% Bias Score
EU Wastewater Directive Faces Legal Challenge Over Costs
The EU's new wastewater directive, effective January 2025, requires pharmaceutical and cosmetic companies to fund 80% of micropollutant removal from wastewater, prompting 16 legal challenges from industry players and Poland due to concerns about increased drug prices and potential shortages.
EU Wastewater Directive Faces Legal Challenge Over Costs
The EU's new wastewater directive, effective January 2025, requires pharmaceutical and cosmetic companies to fund 80% of micropollutant removal from wastewater, prompting 16 legal challenges from industry players and Poland due to concerns about increased drug prices and potential shortages.
Progress
48% Bias Score
Showing 85 to 96 of 152 results